Clover Health Investments, Corp.

As of June 30, 2026, Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A carries a market capitalization of 15.98B, placing it among publicly traded companies globally. Its enterprise value stands at 14.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A has 581.09M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.22, and the price-to-book ratio stands at 8.22.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 14.73B versus a market cap of 15.98B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A posted a negative return on equity (ROE) of -5.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.84, reflecting losses generated across the asset base. The company generates approximately 18.68M in revenue per employee across its workforce of 685.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A's stock has gained approximately 42.87% over the past 52 weeks. The 50-day moving average sits at 23.63, while the 200-day moving average is 16.70.

Over the twelve months ended June 30, 2026, Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A generated 12.80B in revenue and converted that into -94.91M in net income, yielding earnings per share of -0.16. EBITDA reached -85.06M, while operating income came in at -94.91M.

These figures are as of June 30, 2026. Total book value stands at 1.94B, with working capital of 837.98M providing operational flexibility.

Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A produced 398.19M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -14.60M in capital expenditures, free cash flow totaled 383.59M - equivalent to 0.67 per share.

Over the twelve months ended June 30, 2026, Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A posted a gross margin of 18.57, reflecting its pricing power and cost economics. The operating margin of -0.74 and net profit margin of -0.74 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.41, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A shareholders.

As of June 30, 2026, Clover Health Investments Corp. Shs A Unsponsored Brazilian Depositary Receipt Repr 1 Sh A has an Altman Z-Score of 4.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.